Sabrina H Tsang1, Joshua N Sampson1, John Schussler2, Carolina Porras3, Sarah Wagner1,4, Joseph Boland1,4, Bernal Cortes3, Douglas R Lowy1, John T Schiller1, Mark Schiffman1, Troy J Kemp5, Ana Cecilia Rodriguez6, Wim Quint7, Mitchell H Gail1, Ligia A Pinto5, Paula Gonzalez3, Allan Hildesheim1, Aimée R Kreimer1, Rolando Herrero3,8. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2. Information Management Services, Silver Spring, MD, USA. 3. Agencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica. 4. Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, MD, USA. 5. HPV Immunology Laboratory, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 6. Independent Consultant, San José, Costa Rica. 7. DDL Diagnostic Laboratory, Rijswijk, The Netherlands. 8. Early Detection and Prevention Section, International Agency for Research on Cancer, Lyon, France.
Abstract
BACKGROUND: The Costa Rica HPV Vaccine Trial has documented cross-protection of the bivalent HPV vaccine against HPV31/33/45 up to 7 years after vaccination, even with one dose of the vaccine. However, the durability of such protection remains unknown. Here, we evaluate the efficacy of different schedules of the vaccine against HPV31/33/45 out to 11 years postvaccination, expanding to other nontargeted HPV types. METHODS: We compared the rates of HPV infection in vaccinated women with the rates in a comparable cohort of unvaccinated women. We estimated the average vaccine efficacy (VEavg) against incident infections and tested for a change in VE over time. RESULTS: Among 3-dose women, we observed statistically significant cross-protection against HPV31/33/45 (VEavg = 64.4%, 95% confidence interval [CI] = 57.7% to 70.0%). Additionally, we observed borderline, statistically significant cross-protection against HPV35 (VEavg = 23.2%, 95% CI = 0.3% to 40.8%) and HPV58 (VEavg = 21.2%, 95% CI = 4.2% to 35.3%). There was no decrease in VE over time (two-sided Ptrend > .05 for HPV31, -33, -35, -45, and -58). As a benchmark, VEavg against HPV16/18 was 82.0% (95% CI = 77.3% to 85.7%). Among 1-dose women, we observed comparable efficacy against HPV31/33/45 (VEavg = 54.4%, 95% CI = 21.0% to 73.7%). Acquisition of nonprotected HPV types was similar between vaccinated and unvaccinated women, indicating that the difference in HPV infection rates was not attributable to differential genital HPV exposure. CONCLUSIONS: Substantial cross-protection afforded by the bivalent vaccine against HPV31/33/45, and to a lesser extent, HPV35 and HPV58, was sustained and remained stable after 11 years postvaccination, reinforcing the notion that the bivalent vaccine is an effective option for protection against HPV-associated cancers. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
RCT Entities:
BACKGROUND: The Costa Rica HPV Vaccine Trial has documented cross-protection of the bivalent HPV vaccine against HPV31/33/45 up to 7 years after vaccination, even with one dose of the vaccine. However, the durability of such protection remains unknown. Here, we evaluate the efficacy of different schedules of the vaccine against HPV31/33/45 out to 11 years postvaccination, expanding to other nontargeted HPV types. METHODS: We compared the rates of HPV infection in vaccinated women with the rates in a comparable cohort of unvaccinated women. We estimated the average vaccine efficacy (VEavg) against incident infections and tested for a change in VE over time. RESULTS: Among 3-dose women, we observed statistically significant cross-protection against HPV31/33/45 (VEavg = 64.4%, 95% confidence interval [CI] = 57.7% to 70.0%). Additionally, we observed borderline, statistically significant cross-protection against HPV35 (VEavg = 23.2%, 95% CI = 0.3% to 40.8%) and HPV58 (VEavg = 21.2%, 95% CI = 4.2% to 35.3%). There was no decrease in VE over time (two-sided Ptrend > .05 for HPV31, -33, -35, -45, and -58). As a benchmark, VEavg against HPV16/18 was 82.0% (95% CI = 77.3% to 85.7%). Among 1-dose women, we observed comparable efficacy against HPV31/33/45 (VEavg = 54.4%, 95% CI = 21.0% to 73.7%). Acquisition of nonprotected HPV types was similar between vaccinated and unvaccinated women, indicating that the difference in HPV infection rates was not attributable to differential genital HPV exposure. CONCLUSIONS: Substantial cross-protection afforded by the bivalent vaccine against HPV31/33/45, and to a lesser extent, HPV35 and HPV58, was sustained and remained stable after 11 years postvaccination, reinforcing the notion that the bivalent vaccine is an effective option for protection against HPV-associated cancers. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
Authors: S Rachel Skinner; Dan Apter; Newton De Carvalho; Diane M Harper; Ryo Konno; Jorma Paavonen; Barbara Romanowski; Cecilia Roteli-Martins; Nansa Burlet; Attila Mihalyi; Frank Struyf Journal: Expert Rev Vaccines Date: 2016 Impact factor: 5.217
Authors: Aimée R Kreimer; Joshua N Sampson; Carolina Porras; John T Schiller; Troy Kemp; Rolando Herrero; Sarah Wagner; Joseph Boland; John Schussler; Douglas R Lowy; Stephen Chanock; David Roberson; Mónica S Sierra; Sabrina H Tsang; Mark Schiffman; Ana Cecilia Rodriguez; Bernal Cortes; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff Journal: Vaccine Date: 2006-06-19 Impact factor: 3.641
Authors: B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: Rolando Herrero; Sholom Wacholder; Ana C Rodríguez; Diane Solomon; Paula González; Aimee R Kreimer; Carolina Porras; John Schussler; Silvia Jiménez; Mark E Sherman; Wim Quint; John T Schiller; Douglas R Lowy; Mark Schiffman; Allan Hildesheim Journal: Cancer Discov Date: 2011-09-09 Impact factor: 39.397
Authors: Mark H Einstein; Peter Takacs; Archana Chatterjee; Rhoda S Sperling; Nahida Chakhtoura; Mark M Blatter; Jacob Lalezari; Marie-Pierre David; Lan Lin; Frank Struyf; Gary Dubin Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Aimée R Kreimer; Joshua N Sampson; Carolina Porras; John T Schiller; Troy Kemp; Rolando Herrero; Sarah Wagner; Joseph Boland; John Schussler; Douglas R Lowy; Stephen Chanock; David Roberson; Mónica S Sierra; Sabrina H Tsang; Mark Schiffman; Ana Cecilia Rodriguez; Bernal Cortes; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Jaimie Z Shing; Shangying Hu; Rolando Herrero; Allan Hildesheim; Carolina Porras; Joshua N Sampson; John Schussler; John T Schiller; Douglas R Lowy; Mónica S Sierra; Loretto Carvajal; Aimée R Kreimer Journal: Lancet Oncol Date: 2022-06-13 Impact factor: 54.433
Authors: Sally N Adebamowo; Brian Befano; Li C Cheung; Ana Cecilia Rodriguez; Maria Demarco; Greg Rydzak; Xiaojian Chen; Carolina Porras; Rolando Herrero; Jane J Kim; Philip E Castle; Nicolas Wentzensen; Aimée R Kreimer; Mark Schiffman; Nicole G Campos Journal: Int J Cancer Date: 2022-06-17 Impact factor: 7.316
Authors: Carolina Porras; Sabrina H Tsang; Rolando Herrero; Diego Guillén; Teresa M Darragh; Mark H Stoler; Allan Hildesheim; Sarah Wagner; Joseph Boland; Douglas R Lowy; John T Schiller; Mark Schiffman; John Schussler; Mitchell H Gail; Wim Quint; Rebeca Ocampo; Jorge Morales; Ana C Rodríguez; Shangying Hu; Joshua N Sampson; Aimée R Kreimer Journal: Lancet Oncol Date: 2020-12 Impact factor: 41.316
Authors: Sabrina H Tsang; John T Schiller; Carolina Porras; Troy J Kemp; Rolando Herrero; John Schussler; Monica S Sierra; Bernal Cortes; Allan Hildesheim; Douglas R Lowy; Ana Cecilia Rodríguez; Byron Romero; Nicolas Çuburu; Jaimie Z Shing; Ligia A Pinto; Joshua N Sampson; Aimée R Kreimer Journal: NPJ Vaccines Date: 2022-03-29 Impact factor: 7.344
Authors: Ana Paula Costa; Paulo César Giraldo; Ricardo Ney Cobucci; Márcia Lopes Consolaro; Raquel Pantarotto Souza; Luanda Barbara Canário; Paula Renata Machado; Rand Randall Martins; Pedro Vieira Baptista; José Eleutério Jr; Ana Katherine Gonçalves Journal: Asian Pac J Cancer Prev Date: 2020-09-01